Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers
Immune Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Three ways to separate long-term winners from stocks that fizzle.
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...